---
canonical_url: https://www.stockexpertai.com/earnings/bdx
last_updated: 2026-05-05T21:08:06.194Z
---

# Becton, Dickinson and Company (BDX) Q4 FY2026 Earnings Preview

> **[stale-preview-note]** Note: this preview was published before the 2026-05-07 earnings report. Results have since been released — verify against the latest filings.

> This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-05T21:08:05.864Z. Educational tool, not investment advice.

---

## Quick Summary

| Field | Value | Source |
|---|---|---|
| Price | $144.17 (▼ -1.46%) | fmp:quote |
| Market Cap | $52.2B | fmp:profile |
| 52w range | $127.59 – $187.35 | fmp:quote |
| Earnings | Thu 7 May | fmp:earnings-history |
| EPS estimate | $2.77 (-17% YoY) | fmp:earnings-estimate |
| Revenue estimate | $4.7B | fmp:earnings-estimate |
| Beat streak | 8/4 | fmp:earnings-history |
| Rating | B+ (overall 3/5) | fmp:ratings |
| Analyst median target | $168 (+16.5% upside) | fmp:price-target-consensus |
| MoonshotScore | 40/100 | derived |
| Council | 1/6 bullish | derived |
| Munger verdict | Fairly Valued | derived |

## Becton, Dickinson and Company — Q4 FY2026 Expectations

Q4 consensus: revenue <strong data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvgLabel">$4.7B</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvg" title="FMP est">[FMP est]</sup>, EPS <strong data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">$2.77</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg" title="FMP est">[FMP est]</sup>. 8 consecutive quarters of beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.beatStreakCount" title="FMP earnings">[FMP earnings]</sup>.

## Quick Take

**Score:** B+ · **Stance:** BUY · **Council:** 1/6 · **Moonshot:** 40

= MoonshotScore <strong>40</strong><sup class="cite" data-source="derived" data-field="moonshot.score" title="9-pillar formula">[9-pillar formula]</sup> + Council <strong>1/6</strong><sup class="cite" data-source="derived" data-field="council.bullishCount" title="6-lens rule">[6-lens rule]</sup>. Form 4: 0 transactions<sup class="cite" data-source="fmp:insider-trading" data-field="insider.txCount" title="FMP Form 4">[FMP Form 4]</sup>.

## Watchlist (4 metrics)

### 1. Fy26 Eps Guidance

Becton, Dickinson and Company is establishing an adjusted EPS guidance for fiscal year 2026 in a range of $12.35 to $12.65, reflecting growth of approximately 6% at the midpoint, including an impact of 370 basis points from tariffs.

> "Given these considerations, we are establishing an adjusted EPS guidance for new Becton, Dickinson and Company in a range of $12.35 to $12.65. This reflects growth of approximately 6% at the midpoint, including an impact of 370 basis points from tariffs."
> — Vitor Roach, Senior Vice President and Interim Chief Financial Officer, Expectation / Guide · Q1 FY2026

### 2. Operating Margin Decline

Becton, Dickinson and Company's adjusted operating margin decreased to 21.2%, down 240 basis points due to the impact of tariffs and increased commercial investments in key growth areas.

> "Adjusted operating margin of 21.2% was down 240 basis points versus the prior year due to the impact of tariffs and increased commercial investments in key growth areas."
> — Vitor Roach, Senior Vice President and Interim Chief Financial Officer, Risk Indicator · Q1 FY2026

### 3. New Bdx Growth

New Becton, Dickinson and Company grew 2.5%, with broad-based growth across the markets where investments have been increased.

> "New Becton, Dickinson and Company grew 2.5%, with broad-based growth across the markets where we have been doubling down on investments."
> — Thomas E. Polen, Chairman, Chief Executive Officer, and President, Investor Focus · Q1 FY2026

### 4. Eps Decline

Becton, Dickinson and Company's adjusted EPS decreased by 15.2% to $2.91, driven primarily by the impact of tariffs.

> "Adjusted EPS of $2.91 was down 15.2% driven primarily by the impact of tariffs."
> — Vitor Roach, Senior Vice President and Interim Chief Financial Officer, Investor Focus · Q1 FY2026


## MoonshotScore Pillars

| Pillar | Score | Level | Evidence |
|---|---|---|---|
| Revenue Growth | 0.0 | weak | Q1 vs Q2: growth negative (-0.4%, contraction) |
| Gross Margin | 4.0 | medium | Q1: average margin (44.6%) |
| Operating Leverage | 1.0 | weak | op margin average (11.3%) |
| Cash Runway | 10.0 | strong | FCF very strong ($0.5B, 5.1× CapEx) |
| R&D Intensity | 5.0 | medium | average R&D (5.7%) |
| Price Momentum | 4.0 | medium | RSI 30.5 weak momentum, 50d below |
| News Sentiment | 4.0 | medium | mixed (40% buy) |

**Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula.

## Council (7-Lens)

| Name | Stance | Context |
|---|---|---|
| Ray Dalio | bull | macro · target upside +16.5% |
| Ken Griffin | bear | flow · 50d MA below |
| Jim Simons | neutral | quant · RSI 31 |
| Klarman | neutral | value · target upside +16.5% |
| Buffett | neutral | quality · ROE score 3/5 |
| Munger | neutral | valuation · target upside +16.5% |

**Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr.

## Munger Lens

- **Verdict:** Fairly Valued
- **Financial Health:** Moderate
- **Margin of Safety:** Moderate
- **Interest Coverage:** Adequate
- **ROIC vs WACC:** Tight

**Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget.

## Technical Levels

- **RSI(14):** 30.5 — momentum zayıf — oversold yakınında değil ama alıcı baskısı az
- **50d MA:** $159 — hisse %9.4 altında — kısa vadeli direnç
- **200d MA:** $141 — hisse %2.1 üstünde — uzun vadeli destek
- **Volume (10d):** +17%

## Past Performance (4 Quarters)

| Quarter | EPS Actual | EPS Estimate | Result | Reaction |
|---|---|---|---|---|
| Q2 FY25 | $3.35 | $3.28 | BEAT | -0.4% |
| Q3 FY25 | $3.68 | $3.40 | BEAT | +3.1% |
| Q4 FY25 | $3.96 | $3.92 | BEAT | +0.3% |
| Q1 FY26 | $2.91 | $2.21 | +31.7% EPS | +5.3% |

Q1 (February 9, 2026): EPS $2.91 vs $2.21 est<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, +31.7% beat. D+1 movement: +5.3%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP D+1">[FMP D+1]</sup>. Decline despite beat — market reacted to guidance, not numbers.

## 3 Scenarios

### Scenario A · Beat
**Q4 EPS > $2.77 + CapEx discipline**

Threshold: EPS > $2.77<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>.

Target: Break above median target $168<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP target]</sup>; high target $202<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.high">[FMP]</sup> upper bound.

### Scenario B · In-Line
**EPS ≈ $2.77 + CapEx < $108.0M**

Threshold: EPS ≈ $2.77<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>, Q4 CapEx < $108.0M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel">[FMP]</sup>.

Target: Consolidation in the band between current $144<sup class="cite" data-source="fmp:quote" data-field="quote.price">[FMP]</sup> and median $168<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP]</sup>.

### Scenario C · Miss
**EPS < $2.69 or CapEx ≥ $108.0M**

Threshold: EPS < $2.69<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est×0.97]</sup>.

Target: Current $144 below SMA200 $141<sup class="cite" data-source="fmp:technical" data-field="technical.sma200">[FMP]</sup>, if rejection continues, $120<sup class="cite" data-source="derived" data-field="technical.sma200" data-formula="round(sma200*0.85)">[derived]</sup> support activates.

## Risk Notes

### Primary segment below threshold
Q1: EPS $2.91 vs $2.21 beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, stock +5.3% D+1<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP">[FMP]</sup>.

### Backlog concentration
No RPO/backlog concentration disclosed in Q1 earnings call.

### Insider trading
Form 4 data is marked in the table — this page does not generate assumptions for this stock.

| Executive | Action | Amount | Date |
|---|---|---|---|


**Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26

### CapEx shock
Q1 CapEx $108.0M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel" title="FMP cashflow">[FMP cashflow]</sup>. Q1 op margin 11.3%<sup class="cite" data-source="fmp:income" data-field="income.quarters.0.operatingMargin" title="FMP op margin">[FMP op margin]</sup> — this level in Q4 is sensitive to CapEx revision risk.

## Wall Street Consensus

- **Median target:** $168 (+16.5% upside vs current $144)
- **High / Low:** $202 / $159
- **Buy / Hold / Sell:** 6 / 9 / 0
- **Analyst count:** 6 (last quarter), 31 all-time

## Additional Transcript Insights

### 1. new_bdx_growth

**Claim:** New Becton, Dickinson and Company grew 2.5%, with broad-based growth across the markets where investments have been increased.

**Evidence (transcript):** "New Becton, Dickinson and Company grew 2.5%, with broad-based growth across the markets where we have been doubling down on investments."

**Numbers:** 2.5%

### 2. biologic_drug_delivery_growth

**Claim:** Becton, Dickinson and Company delivered double-digit growth in biologic drug delivery.

**Evidence (transcript):** "This includes double-digit growth in biologic drug delivery, PureWick, advanced tissue regeneration, Pharmacy Automation, and high single-digit growth in APM."

**Numbers:** —

### 3. operating_margin_decline

**Claim:** Becton, Dickinson and Company's adjusted operating margin decreased to 21.2%, down 240 basis points due to the impact of tariffs and increased commercial investments in key growth areas.

**Evidence (transcript):** "Adjusted operating margin of 21.2% was down 240 basis points versus the prior year due to the impact of tariffs and increased commercial investments in key growth areas."

**Numbers:** 21.2%, 240

### 4. eps_decline

**Claim:** Becton, Dickinson and Company's adjusted EPS decreased by 15.2% to $2.91, driven primarily by the impact of tariffs.

**Evidence (transcript):** "Adjusted EPS of $2.91 was down 15.2% driven primarily by the impact of tariffs."

**Numbers:** $2.91, 15.2%

### 5. fy26_eps_guidance

**Claim:** Becton, Dickinson and Company is establishing an adjusted EPS guidance for fiscal year 2026 in a range of $12.35 to $12.65, reflecting growth of approximately 6% at the midpoint, including an impact of 370 basis points from tariffs.

**Evidence (transcript):** "Given these considerations, we are establishing an adjusted EPS guidance for new Becton, Dickinson and Company in a range of $12.35 to $12.65. This reflects growth of approximately 6% at the midpoint, including an impact of 370 basis points from tariffs."

**Numbers:** $12.35, $12.65, 6%, 370


---

*Data source: FMP (live query, 2026-05-05), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*
